Resverlogix Corp. (RVX.TO)


Toronto - Toronto Delayed Price. Currency in CAD
1.75-0.15 (-7.89%)
At close: 3:59 PM EDT
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Open1.93
Prev Close1.90
Bid1.70 x
Ask1.75 x
Day's Range1.65 - 1.93
52wk Range1.10 - 2.52
1y Target EstN/A
Market Cap184.11M
P/E Ratio (ttm)-6.39
Beta0.12
Volume158,385
Avg Vol (3m)32,969
Dividend & YieldN/A (N/A)
Earnings DateN/A
  • Zacks Small Cap Research4 days ago

    RVX: BETonMACE Trial Continues: Awaiting First Readout

    On September 14, Resverlogix Corp. (RVX.TO) submitted its financial filings for its first quarter of fiscal year 2017 ending July 31, 2016 to the Alberta Securities Commission.  The company reported no revenues and a net loss of ($6.5) million or ($0.06) per share.  This compares to our estimates also of zero revenues and a net loss of ($4.4) million or ($0.04) per share.  Total operational expenses for 1Q:17 were $7.1 million, increasing from $3.5 million in the same quarter of the prior year.  First quarter research & development expenses rose 183%, while general & administrative fell 27%.  Costs related to the BETonMACE clinical trial drove the overall increase.

  • PR Newswire12 days ago

    Resverlogix Announces Filing of Quarterly Financial Statements and Management's Discussion & Analysis

    CALGARY, Sept. 14, 2016 /PRNewswire/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today that it has filed its unaudited interim Consolidated Financial Statements ...

  • CNW Group12 days ago

    Resverlogix Announces Filing of Quarterly Financial Statements and Management's Discussion & Analysis

    Resverlogix Announces Filing of Quarterly Financial Statements and Management's Discussion & Analysis